WASHINGTON, Feb 22 (Reuters) - Roche Holding AG (ROG.VX: Quote, Profile , Research) had ended its study of heart transplant patients sooner than anticipated after a higher than expected rate of acute organ rejection, U.S. health regulators said on Thursday.
